

Pharmaceutical Policies Updates Effective September 1, 2020

To view all current MVP Health Care® (MVP) Medical policies, *Sign In* at mvphealthcare.com and select *Resources*, then *Medical Policies*. All policies are reviewed at least once annually. This communication lists all impacted policies and their status. Policies fall into one of the following categories:

- **New** – Denotes a new policy.
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs.
- **Review/No Changes**– Policies that have been reviewed but have no content change.
- **Archived** – Denotes a policy that is no longer active.

The following policies are effective September 1, 2020 and will be available for viewing on or before July 1, 2020. Hard copies of the policies are available upon request.

Pharmaceutical Policy Name	Status
Cystic Fibrosis (Select Agents for Inhalation)	Updated
Cystic Fibrosis (Select Oral Agents)	Updated
Xolair	Updated
Idiopathic Pulmonary Fibrosis	Updated
Intranasal Corticosteroids	Updated
Infliximab – effective 5/1/20	Updated
Preventive Services – Medication – effective 5/1/20	Updated
Quantity Limits for Prescription Drugs	Updated
Weight Loss Agents – effective 7/1/20	Updated

To view all communications, visit mvphealthcare.com/FastFax

To receive future FastFax messages by email, send a request to MVPFastFax@mvphealthcare.com.

Questions? Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at 1-800-684-9286.

